This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Johnson SF , Cruz C , Greifenberg AK , Dust S , Stover DG , Chi D , Primack B , Cao S , Bernhardy AJ , Coulson R , Lazaro JB , Kochupurakkal B , Sun H , Unitt C , Moreau LA , Sarosiek KA , Scaltriti M , Juric D , Baselga J , Richardson AL , Rodig SJ , D'Andrea AD , Balmana J , Johnson N , Geyer M , Serra V , Lim E , Shapiro GI
CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer
Cell Rep. 2016 Nov 22;17(9) :2367-2381
PMID: 27880910 PMCID: PMC5176643 URL: https://www.ncbi.nlm.nih.gov/pubmed/27880910
AbstractAlthough poly(ADP-ribose) polymerase (PARP) inhibitors are active in homologous recombination (HR)-deficient cancers, their utility is limited by acquired resistance after restoration of HR. Here, we report that dinaciclib, an inhibitor of cyclin-dependent kinases (CDKs) 1, 2, 5, and 9, additionally has potent activity against CDK12, a transcriptional regulator of HR. In BRCA-mutated triple-negative breast cancer (TNBC) cells and patient-derived xenografts (PDXs), dinaciclib ablates restored HR and reverses PARP inhibitor resistance. Additionally, we show that de novo resistance to PARP inhibition in BRCA1-mutated cell lines and a PDX derived from a PARP-inhibitor-naive BRCA1 carrier is mediated by residual HR and is reversed by CDK12 inhibition. Finally, dinaciclib augments the degree of response in a PARP-inhibitor-sensitive model, converting tumor growth inhibition to durable regression. These results highlight the significance of HR disruption as a therapeutic strategy and support the broad use of combined CDK12 and PARP inhibition in TNBC.
Notes2211-1247 Johnson, Shawn F Cruz, Cristina Greifenberg, Ann Katrin Dust, Sofia Stover, Daniel G Chi, David Primack, Benjamin Cao, Shiliang Bernhardy, Andrea J Coulson, Rhiannon Lazaro, Jean-Bernard Kochupurakkal, Bose Sun, Heather Unitt, Christine Moreau, Lisa A Sarosiek, Kristopher A Scaltriti, Maurizio Juric, Dejan Baselga, Jose Richardson, Andrea L Rodig, Scott J D'Andrea, Alan D Balmana, Judith Johnson, Neil Geyer, Matthias Serra, Violeta Lim, Elgene Shapiro, Geoffrey I Journal Article United States Cell Rep. 2016 Nov 22;17(9):2367-2381. doi: 10.1016/j.celrep.2016.10.077.